There are 2949 resources available
1140P - A digital companion for patients with BRAF-mutant advanced melanoma treated with targeted therapies: TAVIE skin app
Presenter: Peter Mohr
Session: E-Poster Display
Resources:
Abstract
1141P - EXCITE: An analysis of the metastatic melanoma patient experience in the advent of novel therapies using health-related social media
Presenter: Guy Faust
Session: E-Poster Display
Resources:
Abstract
1142P - Treatment of metastatic uveal melanoma (mUM) through genomic profiling
Presenter: Serge Leyvraz
Session: E-Poster Display
Resources:
Abstract
1143P - Nivolumab and ipilimumab (N+I) is active in patients (pts) with metastatic uveal melanoma (mUM) with extra-hepatic only involvement: Pooled analysis from 2 phase II trials
Presenter: Josep Maria Piulats Rodriguez
Session: E-Poster Display
Resources:
Abstract
1144P - Clinical predictors of therapeutic benefit from anti-PD1 immune checkpoint inhibitors (ICI) in patients (pts) with metastatic uveal melanoma
Presenter: April Rose
Session: E-Poster Display
Resources:
Abstract
1145P - Metabolic activity of liver metastases may predict survival in patients with metastatic uveal melanoma
Presenter: Luis del Carpio Huerta
Session: E-Poster Display
Resources:
Abstract
1146P - Rh-endostatin combined with chemotherapy and interferon in the treatment of oral mucosal melanoma without clinical cervical lymph node metastasis: A retrospective study in Chinese population
Presenter: Dongliang Wei
Session: E-Poster Display
Resources:
Abstract
1147P - Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in locally advanced or oligometastatic melanoma: Preliminary results
Presenter: Emilia Cocorocchio
Session: E-Poster Display
Resources:
Abstract
1148P - Multiple primary melanoma incidence trends over five decades, a nationwide population-based study
Presenter: Hildur Helgadottir
Session: E-Poster Display
Resources:
Abstract
1149P - Validation of a model combining clinicopathologic risk factors and a gene expression profile to identify primary melanoma patients who can safely forgo sentinel lymph node biopsy
Presenter: Alexander Meves
Session: E-Poster Display
Resources:
Abstract